← Leaderboards
Brittany Allen-Petersen
Oregon Health & Science University
$1,157,556
Attributed
$1,157,556
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $457.5K · FY2015–25$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,157,556 · 3
By mechanism
K22$524,532 · 1
R01$457,503 · 1
F32$175,521 · 1
Top collaborators
No co-investigators on record.
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Chao-Ling Yang$3,165,412
- Sarah A Byers$49,646
- William Montgomery Yashar$32,248
- Katherine Rosalie Pelz$54,538
Others in their field
Top investigators on “Therapy Resistant”
- Gregory H Reaman · National Childhood Cancer Foundation$219,720,500
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,910,108
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Ralph Parchment · Leidos Biomedical Research, Inc.$135,017,102
- Peter C Adamson · National Childhood Cancer Foundation$114,476,581
- Constance Ann Benson · University Of California, San Diego$97,167,982
Research focus
Therapy ResistantPhenotypeResistanceSurvival RateMalignant NeoplasmsPathway InteractionsMouse ModelRegulationSignal TransductionPancreasLesionKras2 GeneMalignant Neoplasm Of PancreasCancer CellMediatingCancer EtiologyPhosphorylationPlayPancreatic Ductal AdenocarcinomaCessation Of LifeNew Therapeutic TargetOncogenicIn VitroTumor
Grant awards (7)
Posttranslational regulation of macropinocytosis in pancreatic cancer$457,503
R01 · FY2025 · CA · contact PI
The role of PP2A B56a in pancreatic tumorigenesis$174,844
K22 · FY2022 · CA · contact PI
The role of PP2A B56a in pancreatic tumorigenesis$174,844
K22 · FY2021 · CA · contact PI
The role of PP2A B56a in pancreatic tumorigenesis$174,844
K22 · FY2020 · CA · contact PI
MYC is a critical downstream effector in KRAS-driven pancreatic cancer$60,990
F32 · FY2017 · CA · contact PI
MYC is a critical downstream effector in KRAS-driven pancreatic cancer$58,002
F32 · FY2016 · CA · contact PI
MYC is a critical downstream effector in KRAS-driven pancreatic cancer$56,529
F32 · FY2015 · CA · contact PI